NCT06510465View on ClinicalTrials.gov

Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2032

Conditions
Breast Cancer
Interventions
DRUG

utidelone

utidelone 50mg／m2，ivgtt，d1，8，15，22, q28d, up to 4 cycle；

DRUG

Cisplatin

cisplatin25mg/m2，ivgtt，d1，8，15；q28d, up to 4 cycle.

DRUG

Trastuzumab

Trastuzumab 8mg/kg, ivgtt, d1, then 6mg/kg, q21d or Trastuzumab 4mg/kg, ivgtt, d1, then 2mg/kg, q7d or Trastuzumab Injection（Subcutaneous Injection）600mg，subcutaneous Injection，d1，q21d

DRUG

Pertuzumab

Pertuzumab 840mg, ivgtt, d1, then 420mg, q21d or Pertuzumab/trastuzumab/hyaluronidase

Trial Locations (2)

200127

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai

Unknown

Renji Hospital, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER